BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 1998

View Archived Issues

Megabios seeks partners for oncology programs

Read More

University of Pittsburgh researcher awarded grant to study dendritic cell use in transplantation

Read More

BTG: preliminary year-end 1998 highlights

Read More

Genta to commence phase I/IIa trial with G-3139

Read More

Interim report on phase I testing of bizelesin, a bifunctional alkylating agent

Read More

Diatide's NDA for lung cancer imaging agent receives priority review

Read More

Immunomedics and Beckman Coulter form joint venture for cancer therapeutics

Read More

FDA approves first new drug for tuberculosis in 25 years

Read More

Aviron and CSL enter collaboration for FluMist

Read More

Sibia Neurosciences initiates phase I trial with SIB-1553A

Read More

Verapamil prodrug enhances activity of cytotoxic agents in resistant cell lines

Read More

German scientists synthesize novel apoptosis-inducing agents

Read More

Progenics and Pharmacopeia to jointly discover small-molecule HIV drugs

Read More

Compounds for the treatment of HIV infection developed at Janssen

Read More

Mylan to acquire Penederm

Read More

Cathepsin B and L inhibitors claimed by Canadian researchers

Read More

Astra discloses immunomodulatory peptides for oral administration

Read More

HMR discloses preparation and use of series with MMP-inhibitory activity

Read More

Celltech scientists discover potent and selective inhibitors of protein kinases

Read More

French investigators evaluate potential cell-free antitumor vaccine

Read More

HMR withdraws cerebral metabolic enhancer from Japanese market; development in AD continues

Read More

Quadramet approved in Canada

Read More

Interference with production of virulence factors as novel antibacterial strategy

Read More

Ziagen submitted for approval in U.S. and Europe

Read More

U.K. investigators identify interesting candidate for clinical evaluation

Read More

FDA says Salix ulcerative colitis Rx approvable

Read More

Clinical trials with ImaRx ultrasound agent initiated in Japan by Yamanouchi

Read More

Phytopharm's alopecia treatment enters phase II testing

Read More

Potential use of BSH in boron neutron capture therapy evaluated in clinical trials

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing